Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hormone therapy controversy raises drug safety issues

17.02.2005


The history of hormone therapy drugs – once thought of as almost magic pills to keep women healthy, vital and young – shows why it is so important to conduct research studies to identify the risks and benefits of drugs, say researchers from Wake Forest University Baptist Medical Center.



"The hormone therapy debate is one more example of a larger issue: are the medications that doctors prescribe safe, and do the benefits outweigh any risks?" said Michelle Naughton, Ph.D., lead author of an article in the current issue of Journal of Social Issues.

The researchers review the 75-year history of hormone therapy (HT), including the Women’s Health Initiative (WHI) research that found increased risk of breast cancer, dementia, heart attacks and strokes in women taking combination hormone therapy – and increased risk of strokes in women taking estrogen alone. Naughton and co-authors Alison Snow Jones, Ph.D., and Sally Shumaker, Ph.D., all from Wake Forest Baptist, examine why there has been so much controversy surrounding the research findings and why many women and physicians are reluctant to accept the "lost promise" of HT. HT gained popularity in the 1950s and 1960s and is considered the best treatment for hot flashes and night sweats, which affect as many as two-thirds of menopausal women in the United States. But HT was also marketed as a way women could retain a youthful appearance and stave off the aging process and was prescribed for prevention of heart disease and dementia.


What began as a therapy for bothersome menopausal symptoms that dissipate within a couple of years for most women, became a potential long-term therapy for the prevention and treatment of three of the most common health issues for women – heart disease, dementia and osteoporosis, write the authors. "The intent was good," said Naughton, an associate professor of public health sciences. "There was some evidence showing the drugs might be beneficial for heart disease and dementia," she said, "but the WHI, a large-scale, scientifically conducted clinical trial, found otherwise."

Yet even after the WHI research, which the authors say the Food & Drug Administration found to be definitive, controversy continues about the study results and about use of HT. "In the face of such strong evidence that, at a minimum, HT does not help the postmenopausal woman beyond the osteoporosis benefit … and can actually harm the aging woman, why has there been resistance among many physicians and women to changing beliefs and practice patterns?" the researchers ask. They conclude that the conflicting interests of women, physicians and drug companies played a role in the popularity of HT (at one time it was one of the most commonly prescribed drugs in the United States) and fuel the continued controversy. They examine the issue from the perspectives of the various stakeholders. For women in the United States, who can expect to live a third or more of their lives after menopause, the stakes are a higher quality of life through their later years. In spite of evidence to the contrary, some women continue to believe that hormone therapy will provide them with better health, the authors said.

Health care professionals are influenced by the needs of their patients and well as information provided by drug manufacturers. In addition, they make their decisions based on years of clinical experience with HT, and may be reluctant to change prescribing patterns based on research findings that small numbers of study participants suffered adverse affects. "Physicians have learned that hormone therapy does provide relief to their patients," the authors write. "How can a drug that does such immediate good, and that appeared to do such long-term good, be so wrong?"

For hormone manufacturers, the stakes are millions of dollars in revenue. HT revenues were reported to be about $2.5 billion a year prior to the WHI study and sales fell to $266 million in the first quarter of 2004. Drug companies work to identify and promote drugs that offer the most promise to patients, but also must consider benefits to their stockholders.

Naughton said the HT controversy, as well as recent controversy surrounding Vioxx and other pain medications, raise issues about drug safety. "Implications of these controversies are the need for better mechanisms for establishing drug safety and monitoring, including the reporting of negative as well as positive trials of new or approved drugs," she said.

Karen Richardson | EurekAlert!
Further information:
http://www.wfubmc.edu

More articles from Health and Medicine:

nachricht Electrical 'switch' in brain's capillary network monitors activity and controls blood flow
27.03.2017 | Larner College of Medicine at the University of Vermont

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Big data approach to predict protein structure

27.03.2017 | Life Sciences

Parallel computation provides deeper insight into brain function

27.03.2017 | Life Sciences

Weather extremes: Humans likely influence giant airstreams

27.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>